S&P 500
$5,842.01
-0.0%
-$2.60
DJI
$41,859.09
-0.0%
-$1.35
NASDAQ
$18,925.73
+0.3%
+$53.09
Bitcoin
111,239.00
+0.5%
+551.68
AAPL
$201.16
-0.5%
-$0.93
AMZN
$202.96
+0.9%
+$1.84
GOOG
$171.96
+1.1%
+$1.90
META
$636.81
+0.2%
+$1.31
MSFT
$454.60
+0.4%
+$2.03
NVDA
$132.90
+0.8%
+$1.10
TSLA
$341.59
+2.1%
+$6.97
NewAmsterdam Pharma (NASDAQ: NAMS)
$18.24
(-1.5%)
-$0.27
Price as of May 22, 2025, 3:58 p.m. ET
NewAmsterdam Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
NewAmsterdam Pharma Company Info
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.